EGFR Biomarker | Hope With Answers℠

Currently, the biomarkers that have been identified for potential targeted therapy treatments for lung cancer are: EGFR, ALK, KRAS, MET, HER2, ROS1, BRAF, RET, NTRK1, PID3CA, MED1, VEGFR2, HER3, and IGF-1R.  Of those, so far only EGFR, ALK and ROS1 have treatments approved by the FDA. However, there are many more treatments that are in clinical trials.

In this section of the Hope With Answers series, learn more about the EGFR biomarker and the most current information available regarding approved treatments for lung cancer patients with the EGFR mutation.

Hope With Answers℠ Video Series: Biomarker EGFR

Watch Dr. Natasha Leighl of Princess Margaret Hospital in Toronto discusses the EGFR mutation in lung cancer with patient and advocate Jill Feldman. Then watch Dr. Natasha Leighl discusses more details of the EGFR mutation in lung cancer with patient and advocate Ivy Elkins.

Get tested for all biomarkers at once?

New study shows it's cost effective.

Next-generation sequencing can identify hundreds from a small tissue sample at once.

Living with lung cancer

She didn't think they were right

The value of a second opinion: Self-advocacy in the face of lung cancer.

Recently diagnosed?

Learn more about personalized therapies

LCFA’s Personalized Therapies for Lung Cancer brochure is a free, printable resource for you, your caregivers and your doctor.